Sign in
Taking people in New ZealandPhase 1

First-in-human study of KT502 in adults with rheumatoid arthritis

Tests KT502, given under the skin, in adults with rheumatoid arthritis.

Key facts

Who runs it
Kali Therapeutics, Inc.
Where
Auckland, New ZealandSee the siteAlso in 1 other country, 1 site
Trial code
Registry title
A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA)
Status
Recruiting
Phase
Phase 1
People taking part
27 people, planned
Started
13 Jul 2026
Expected to end
Jul 2028
Type of study
Interventional, 2 groups
Treatments tested
  • KT502
Record updated
11 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with active rheumatoid arthritis who did not respond well enough to earlier treatment. It tests a new drug, KT502, given under the skin.

Age
18 to 75 years
Sex
All sexes can join.
Disease stage
Rheumatoid arthritis diagnosed at least 6 months ago, and moderately to severely active.
Earlier treatment
Inadequate response to earlier treatment, as defined in the protocol. Stable use of traditional DMARDs is allowed.
Biomarker or test result
RF positive or ACPA positive.

Main reasons for not taking part

  • Functional class IV rheumatoid arthritis
  • Any other autoimmune disease
  • Active infection, or a history of serious recurrent or chronic infection
  • Cancer within 5 years, or breast cancer within 10 years
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 18 criteriaShow less

Other criteria

  • Inclusion:
  • 18 to 75 years old
  • Diagnosis of adult-onset RA for at least 6 months
  • Moderately to severely active RA
  • Inadequate treatment response as defined in the protocol
  • RF + or ACPA+
  • Stable use of traditional DMARDs is permitted
  • Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions; Exclusion:
  • Functional class IV as defined by the ACR Classification of Functional Status in RA
  • Presence of any concomitant autoimmune disease other than RA
  • Active infection, history of serious recurrent or chronic infection
  • History of progressive multifocal leukoencephalopathy
  • Have a diagnosis or history of malignant disease within 5 years or breast cancer diagnosed within the previous 10 years
  • History of or planned organ transplant and/or autologous or allogeneic hematopoietic stem cell transplantation
  • Receipt of live vaccine within 4 weeks
  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after study
  • Women who are pregnant or breastfeeding
  • Significant or uncontrolled medical disease that would preclude participant participation

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial is currently available in New Zealand.

Also in 1 other country, 1 site

  • Auckland, NZHospital not named in the registryTaking people

About the trial

What the trial wants to find out

This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT502 administered subcutaneously to participants with Rheumatoid Arthritis (RA). The study will have 2 parts: Part A is a single ascending dose finding (SAD) and Part B is dose escalation by fractionated dosing.

The 2 groups in the trial

  • Part A (SAD): Non-Fractionated Single Ascending Doses / Dose FindingTreatment being tested

    Participants will receive a KT502 Subcutaneous Injection at an assigned dose as on Day 1

    Treatment: KT502

  • Part B: Fractionated Dosing / Dose EscalationTreatment being tested

    Participants will receive a KT502 Subcutaneous Injection as a step-up/fractionated dosing on Day 1 and Day 8

    Treatment: KT502

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1, Open-Label, First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KT502 by Subcutaneous Administration in Adult Participants With Rheumatoid Arthritis
Plain-language title
First-in-human study of KT502 in adults with rheumatoid arthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT07564154, who can take part
Record updated
11 August 2026